Applied DNA Sciences Inc APDN:NASDAQ

Applied DNA Sciences (APDN) said Friday its Applied DNA Clinical Labs unit filed a request with the US Food and Drug Administration for emergency use authorization of its Linea 2.0 COVID-19 reverse transcription polymerase chain reaction assay and at-home sample collection kit.

The assay was designed to detect all known variants of the virus that causes COVID-19, the company said. It received conditional approval from the New York State Department of Health in late December.

The sample collection kit enables the collection of own nasal swab specimens without supervision by medical personnel. Samples are mailed to Applied DNA Clinical Labs with results available in 24 to 48 hours, the company said.

Shares were down 1.5% in recent trading Friday.

Price: 3.90, Change: -0.01, Percent Change: -0.26